Genomics, Circuits, and Pathways in Clinical Neuropsychiatry

Dennis Velakoulis

Section 3 Clinical Phenomenology

25. Intro: Risk Overlap Among Disorders

Patrick Sullivan

26. The conundrum of Clinical Characterization RDOC/ICD-10/DSM

Bruce N. Cuthbert

27. Schizophrenia

Aiden Corvin

28. Psychosis

Raquel E. Gur and Ruben Gur

29. ASD

Rebecca Ann Muhle, Stephan Sanders, Hannah Reed and Matthew William State

30. Bipolar Disorder

Nelson B. Freimer, Carrie E. Bearden and Peter Zandi

31. MDD

David C. Glahn

32. Speech and Language Disorders

Marilu Gorno-Tempini

33. Molecular Pathways Leading to the Clinical Phenomenology of Frontotemporal Dementia

Suzee Eurie Lee and Jennifer S. Yokoyama

34. Alzheimer's

Rudy Tanzi

35. PTSD

Kerry Ressler

36. Neurodevelopmental syndromes

Elliott Sherr

37. Epilepsies

Ryan S. Dhindsa, Daniel Lowenstein and David Goldstein

38. Substance Abuse

Nii Addy

39. Neuroimmunology

Emmanuel Mignot

40. Brain Tumors

Vanessa Clark and Murat Günel

41. White Matter Disorders

Michael David Geschwind and Brianne Magouirk Bettcher

42. ALS

Elena Ratti and James Berry

43. Eating Disorders

Cynthia M. Bulik and Garret Stuber

Section 4 Clinical Translation and Drug Development

44. Pharmacogenomics

Roy H. Perlis

Imaging and Emotions. He oversees a healthy aging program, which includes an artist in residence program. In addition, he helps lead two philanthropy-funded research consortia, the Tau Consortium and Consortium for Frontotemporal Research, focused on developing treatments for tau and progranulin disorders, respectively. Also, he works with the National Football League to help with the education and assessment of players related to brain health. Dr. Miller teaches extensively, runs the Behavioral Neurology Fellowship at UCSF, and oversees visits of more than 50 foreign scholars every year.

Dr. Miller has received many awards including the Potamkin Award from the American Academy of Neurology, the Raymond Adams Lecture at the American Neurological Association, the Elliot Royer Award from the San Francisco Neurological community, the UCSF Annual Faculty Research Lectureship in Clinical Science, the UCSF Academic Senate Distinction in Mentoring Award, Distinguished Service to Minorities, from Charles Drew University, and the Gene D. Cohen Research Award in Creativity and Aging from the National Center for Creative Aging. He has authored The Human Frontal Lobes, The Behavioral Neurology of Dementia, Frontotemporal Dementia and over 600 other publications regarding dementia. He has been featured in Fortune magazine and The New York Times, as well as on "Charlie Rose," "PBS NewsHour" and other media. For more than three decades, Dr. Miller has been the scientific director for the philanthropic organization The John Douglas French Alzheimer's Foundation, a private philanthropic organization that funds basic science research in Alzheimer's disease. Matthew W. State MD, PhD, is a child psychiatrist and human geneticist studying pediatric neuropsychiatric syndromes. His lab focuses on gene discovery as a launching point for efforts to illuminate the biology of these conditions and to develop novel and more effective therapies.



Dr. State received his undergraduate and medical degrees at Stanford University, completed his residency in psychiatry and fellowship in child psychiatry at the UCLA Neuropsychiatric Institute, and earned a PhD in genetics from Yale University. He was on the faculty at Yale from 2001 to 2013 where he was the Donald J. Cohen Professor of Child Psychiatry, Psychiatry and Genetics and the Co-Founder and Co-Director of the Yale Program on Neurogenetics. He is currently the Oberndorf Family Distinguished Professor and Chair of Psychiatry at UCSF and Director of the Langley Porter Psychiatric Institute and Hospital.